Preliminary Clinical Application Study on the Imaging Effects of Novel Cardiac Sympathetic Nerve Imaging Agent 18F-FPMBBG
10.3969/j.issn.1000-3614.2025.03.005
- VernacularTitle:新型心脏交感神经显像药物4-18氟-氟代二乙氧基-3-溴苄基胍的初步临床应用研究
- Author:
Min JU
1
;
Wanjie REN
;
Ke WANG
;
Zongyao ZHANG
;
Kai HAN
;
Xiaodi WANG
;
Yumin ZHENG
;
Lei WANG
;
Wei FANG
Author Information
1. 中国医学科学院 北京协和医学院 国家心血管病中心 阜外医院 核医学科,北京 100037
- Publication Type:Journal Article
- Keywords:
heart failure;
cardiac sympathetic nerve imaging;
norepinephrine transporter;
positron emission tomography
- From:
Chinese Circulation Journal
2025;40(3):234-239
- CountryChina
- Language:Chinese
-
Abstract:
Objectives:To evaluate the imaging effects of the novel sympathetic nerve imaging agent 18F-FPMBBG in healthy volunteers and heart failure patients.Methods:Four healthy volunteers and four heart failure patients were selected to undergo 18F-FPMBBG positron emission tomography/computed tomography(PET/CT)dynamic imaging,the radioactivity distribution characteristics of 18F-FPMBBG in the heart and adjacent organs of the two groups were observed,and the uptake of 18F-FPMBBG by the left ventricular myocardium was compared in the two groups.Results:No adverse effects were observed in all subjects after intravenous injection of 18F-FPMBBG.In healthy volunteers,the heart uptake was rapid and stable,lung uptake was very low,and the blood pool and liver clearance were fast.The heart/liver uptake ratios at 30,60,and 90 minutes after injection were 2.33±0.81,3.29±0.90 and 3.80±1.07,respectively.The average standard uptake value(SUVmean)of 18F-FPMBBG in the heart failure group was significantly lower than that in the healthy volunteer group(P=0.003).The washout rate(WR)was significantly higher in the heart failure group([16.53±2.76]%vs.[3.88±4.51]%,P=0.003).Conclusions:18F-FPMBBG showed good imaging and diagnostic effects in the preliminary imaging of healthy subjects and heart failure patients,and it has the potential to become an ideal cardiac sympathetic nerve imaging agent.
